Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enfortumab vedotin
- Development stage
- Approved
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Enfortumab vedotin is an antibody-drug conjugate (ADC) targeting Nectin-4, a cell adhesion molecule highly expressed in urothelial cancers. The drug consists of a fully human monoclonal antibody directed against Nectin-4 linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon binding to Nectin-4 on tumor cells, the ADC is internalized and MMAE is released intracellularly, leading to cell cycle arrest and apoptosis. Enfortumab vedotin was developed primarily for the treatment of locally advanced or metastatic urothelial carcinoma (bladder cancer), especially in patients who have received prior PD-1/PD-L1 inhibitors and platinum-based chemotherapy or are ineligible for cisplatin-containing regimens[3][5]. It has demonstrated significant improvements in overall survival and progression-free survival both as monotherapy and in combination with pembrolizumab[1][7].
- Brand names
- Padcev
- Other names
- enfortumab vedotin-ejfv恩朗苏拜单抗
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on enfortumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enfortumab vedotin.